ReviewJournal of Korean medical science2020
Perspectives of Immune Therapy in Coronavirus Disease 2019.
Review in Journal of Korean medical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.JMIR public health and surveillance · 2021Pooled it
- Role of epinephrine in attenuating cytokine storm, decreasing ferritin, and inhibiting ferroptosis in SARS-CoV-2.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Article
- [The impact of COVID-19 in a cohort of patients with systemic sclerosis].Revista medica del Instituto Mexicano del Seguro Social · 2023Article
- An overview on the treatments and prevention against COVID-19.Virology journal · 2023Review
- From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Review
- Connecting the Dots in Emerging Mast Cell Research: Do Factors Affecting Mast Cell Activation Provide a Missing Link between Adverse COVID-19 Outcomes and the Social Determinants of Health?Medical sciences (Basel, Switzerland) · 2022Review
- Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab')2 fragment derived from equine polyclonal antibodies.Toxicology and applied pharmacology · 2022Article
- Formulating Hypotheses for Different Study Designs.Journal of Korean medical science · 2021Review
- Pathophysiology and Clinical Presentation of COVID-19 in Children: Systematic Review of the Literature.Maedica · 2021Article
- COVID-19 and the clinical course of rheumatic manifestations.Clinical rheumatology · 2021Review
- Management of Patients with Connective Tissue Disease-associated Interstitial Lung Diseases During the COVID-19 Pandemic.Turkish thoracic journal · 2021Article
- Review
- SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis.Rheumatology international · 2021Review
- [Relationship between MMR vaccination and severity of Covid-19 infection. Survey among primary care physicians].Medicina clinica · 2021Observational
- Relationship between MMR vaccination and severity of Covid-19 infection. Survey among primary care physicians.Medicina clinica (English ed.) · 2021Article
- Public interest in rheumatic diseases and rheumatologist in the United States during the COVID-19 pandemic: evidence from Google Trends.Rheumatology international · 2021Observational
- Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic.Rheumatology international · 2021Review
- When Does the Cytokine Storm Begin in COVID-19 Patients? A Quick Score to Recognize It.Journal of clinical medicine · 2021Article
- An analysis of hematological, coagulation and biochemical markers in COVID-19 disease and their association with clinical severity and mortality: an Indian outlook.American journal of blood research · 2021Article
- COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus.International immunopharmacology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global fight against coronavirus disease 2019 (COVID-19) is largely based on strategies to boost immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent its severe course and complications. The human defence may include antibodies which interact with SARS-CoV-2 and neutralize its aggressive actions on multiple organ systems. Protective cross-reactivity of antibodies against measles and other known viral infections has been postulated, primarily as a result of the initial observations of asymptomatic and mild COVID-19 in children. Uncontrolled case series have demonstrated virus-neutralizing effect of convalescent plasma, supporting its efficiency at early stages of contracting SARS-CoV-2. Given the variability of the virus structure, the utility of convalescent plasma is limited to the geographic area of its preparation, and for a short period of time. Intravenous immunoglobulin may also be protective in view of its nonspecific antiviral and immunomodulatory effects. Finally, human monoclonal antibodies may interact with some SARS-CoV-2 proteins, inhibiting the virus-receptor interaction and prevent tissue injury. The improved understanding of the host antiviral responses may help develop safe and effective immunotherapeutic strategies against COVID-19 in the foreseeable future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.